Amneal Pharmaceuticals, Inc. reported $3.12B of revenue over the trailing twelve months, +9.3% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.12B (to Q2 2026). Net income: $157M, trailing twelve months to Q2 2026. Free cash flow: $128M, trailing twelve months to Q2 2026. Operating margin: 15%, trailing twelve months to Q2 2026.

AMRXAmneal Pharmaceuticals, Inc.

Healthcare

$19.92+103% 1Y

$19.92

$9.6052 weeks$20.49

AMRX as reported

Amneal Pharmaceuticals, Inc. reported $3.12B of revenue over the trailing twelve months, +9.3% on the year before. 11 reported series are charted on this page, each one as filed.

$3.12B

Revenue, trailing twelve months · to Q2 2026 · +9.3% against the twelve months before

Net income: $157M
Net income · +4563% year on year · trailing twelve months to Q2 2026
Free cash flow: $128M
Free cash flow · −55% year on year · trailing twelve months to Q2 2026
Operating margin: 15%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AMRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.12B	+9.3%	Q2 2026
Net income	$157M	+4563%	Q2 2026
EPS	$0.49	+4800%	Q2 2026
Gross margin	39%	n/a	Q2 2026
Operating margin	15%	n/a	Q2 2026
Net margin	5.1%	n/a	Q2 2026
ROE	25%	n/a	Q2 2026
ROA	2.4%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free cash flow	$128M	−55%	Q2 2026
P/E	40.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.